

Resource Summary Report

Generated by [NIF](#) on Sep 20, 2026

EJM

RRID:CVCL_2030

Type: Cell Line

Proper Citation

RRID:CVCL_2030

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2030

Proper Citation: RRID:CVCL_2030

Description: Cell line EJM is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Plasma cell myeloma

Defining Citation: [PMID:1373872](#), [PMID:2117464](#), [PMID:10087940](#), [PMID:10557056](#), [PMID:10936422](#), [PMID:11157491](#), [PMID:17692805](#), [PMID:18647998](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:30285677](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:32123307](#), [PMID:35839778](#)

Comments: Characteristics: Produces IgG lambda (PubMed=2117464)., Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: EJM

Cross References: CLO:CLO_0009835, EFO:EFO_0006572, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioSample:SAMN03472928, BioSample:SAMN10989569, cancercellines:CVCL_2030, Cell_Model_Passport:SIDM01048, ChEMBL-Cells:ChEMBL4295413, ChEMBL-Targets:ChEMBL4296413, Cosmic:720776, Cosmic:742955, Cosmic:2081379, Cosmic:2367286, Cosmic-CLP:1297447, DepMap:ACH-000821, DSMZ:ACC-560,

DSMZCellDive:ACC-560, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:1297447, GEO:GSM827296, GEO:GSM887003, GEO:GSM888072, GEO:GSM1669760, IARC_TP53:358, LiGeA:CCLE_840, LINCS_LDP:LCL-2042, Lonza:1540, PharmacDB:EJM_329_2019, PRIDE:PXD030304, Progenetix:CVCL_2030, PubChem_Cell_line:CVCL_2030, Wikidata:Q54832179

ID: CVCL_2030

Record Creation Time: 20220427T215831+0000

Record Last Update: 20260920T002529+0000

Ratings and Alerts

No rating or validation information has been found for EJM.

No alerts have been found for EJM.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Tiwari PK, et al. (2026) An orally active dual CBP/p300 degrader targets core dependencies of multiple myeloma. Cell reports, 45(6), 117464.

Dupéré-Richer D, et al. (2024) KDM6A Regulates Immune Response Genes in Multiple Myeloma. bioRxiv : the preprint server for biology.

Wang H, et al. (2024) CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells. Cancer biology & therapy, 25(1), 2314322.

Bolomsky A, et al. (2024) IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma. Cancer cell, 42(7), 1185.

Vazquez-Lombardi R, et al. (2022) High-throughput T cell receptor engineering by functional screening identifies candidates with enhanced potency and specificity. Immunity, 55(10), 1953.

Vannam R, et al. (2021) Targeted degradation of the enhancer lysine acetyltransferases CBP and p300. Cell chemical biology, 28(4), 503.

Mondala PK, et al. (2021) Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruption. Cell stem cell, 28(4), 623.